Stefani Wolff

This profile gathers the share dealings of Stefani Wolff across 2 companies, led by Principia Biopharma Inc. and Nurix Therapeutics, Inc. Over a trading history stretching from 16 December 2019 to 1 May 2023, the count stands at 25 filings.

The open-market record consists of 16 sales worth €1.3M, with no purchase. Outside the open market, there are 7 option exercises. 2023 to date brings no purchases and 2 sales.

Most recently, on 2 May 2023, the filings show an open-market sale worth €3,080 in Nurix Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.